Engineering AAV Vectors to Evade Antibody Neutralization
设计 AAV 载体以逃避抗体中和
基本信息
- 批准号:7442123
- 负责人:
- 金额:$ 36.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-06-08 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAnimalsAntibodiesBiologyCD8B1 geneCapsidCapsid ProteinsClinicComplementDependovirusDiseaseEngineeringErythropoietinGene DeliveryGenesHumanImmuneImmune responseImmune systemImmunologyIn VitroIndividualLaboratoriesLibrariesLiverMediatingMedicineMolecularMolecular BiologyMusclePersonal SatisfactionPhenotypePoint MutationPopulationPropertyResistanceRoleSafetySerotypingSerumT-LymphocyteTechnologyTherapeuticVariantVirusWorkadeno-associated viral vectorbasecellular transductiondirected evolutiongene therapyhigh throughput screeningin vivoinsightmutantnovelnovel strategiesreceptor bindingresponsetherapeutic genevectorviral gene deliveryvirology
项目摘要
DESCRIPTION (provided by applicant): Gene therapy has vast potential for treating and potentially curing a wide variety of disorders. However, gene delivery technologies require significant improvements in safety, efficiency, and expression stability before the majority of these diseases can be treated. Vectors based on adeno-associated virus (AAV) have proven themselves to be highly promising, both in the laboratory and the clinic, but they still suffer from several shortcomings. In particular, the majority of the human population has been exposed to AAV serotype 2, as well as other serotypes, and as a result the immune system is primed to neutralize AAV. Antibody neutralization of AAV vectors is an established problem, and cellular immune responses may also be a challenge. We will attempt to solve the former problem and will further investigate basic mechanisms involved in the latter. For the former, we have developed novel directed evolution technology to generate new mutants of AAV with new properties. Specifically, large libraries of virus with random point mutations in the capsid gene encoding the viral coat protein are generated, and variants with novel properties are selected using high throughput screens. We have utilized this approach to generate variants with altered receptor binding properties, as well as variants that escape neutralization by antibodies that greatly inhibit AAV gene delivery by the wild type capsid or coat proteins. We will study the potential of human antibody evading variants to mediate high efficiency gene delivery of the therapeutic gene erythropoietin to the muscle and liver of animals carrying anti-AAV antibodies. In addition, while AAV neutralization by antibodies is an established problem, much less is known about AAV interactions with other components of the immune system. Therefore, the basic mechanisms of immune neutralization of this virus by complement [and T cells] will be investigated to both in vitro and in vivo. In summary, viruses have naturally evolved for their own ends, which do not always meet the needs of a human therapeutic. The novel approaches developed in this work to re-evolve viruses into enhanced human therapeutics will therefore have broad and general impact on the molecular engineering of enhanced viral gene delivery vehicles, including alternate AAV serotypes as well as other vectors. Furthermore, it will yield insights into the responses of other immune system components to AAV.
描述(由申请人提供):基因疗法在治疗和潜在治愈各种疾病方面具有巨大的潜力。然而,基因传递技术需要在安全性、有效性和表达稳定性方面有显著的改进,才能治疗这些疾病中的大多数。基于腺相关病毒(AAV)的载体在实验室和临床上都被证明是非常有前途的,但它们仍然存在一些缺点。特别是,大多数人已经接触了AAV 2型以及其他血清型,因此免疫系统已经准备好中和AAV。AAV载体的抗体中和是一个既定的问题,细胞免疫反应也可能是一个挑战。我们将尝试解决前者的问题,并将进一步研究后者涉及的基本机制。对于前者,我们开发了新的定向进化技术来产生具有新特性的AAV新突变体。具体地说,产生在编码病毒外壳蛋白的衣壳基因中具有随机点突变的大型病毒库,并使用高通量筛选来选择具有新特性的变体。我们利用这种方法来产生具有改变的受体结合性质的变异体,以及逃脱抗体的中和变异体,抗体极大地抑制了野生型衣壳或外壳蛋白的AAV基因传递。我们将研究人类抗体躲避变异体介导治疗性基因促红细胞生成素高效基因传递到携带抗AAV抗体的动物的肌肉和肝脏的可能性。此外,虽然AAV被抗体中和是一个既定的问题,但对AAV与免疫系统其他组成部分的相互作用知之甚少。因此,补体[和T细胞]免疫中和该病毒的基本机制将在体外和体内进行研究。总而言之,病毒是为了它们自己的目的而自然进化的,这并不总是满足人类治疗的需要。因此,在这项工作中开发的将病毒重新进化为增强型人类疗法的新方法将对增强型病毒基因输送载体的分子工程产生广泛和普遍的影响,包括替代AAV血清型以及其他载体。此外,它还将深入了解其他免疫系统组件对AAV的反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID V SCHAFFER其他文献
DAVID V SCHAFFER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID V SCHAFFER', 18)}}的其他基金
Biology and Biotechnology of Cell and Gene Therapy
细胞和基因治疗生物学和生物技术
- 批准号:
10090424 - 财政年份:2021
- 资助金额:
$ 36.12万 - 项目类别:
In Vivo Directed Evolution of Adeno-Associated Virus Vectors for Glioblastoma Multiforme Tumor-Initiating Cells
多形性胶质母细胞瘤肿瘤起始细胞腺相关病毒载体的体内定向进化
- 批准号:
9353802 - 财政年份:2016
- 资助金额:
$ 36.12万 - 项目类别:
Engineering AAV Vectors to Evade Antibody Neutralization
设计 AAV 载体以逃避抗体中和
- 批准号:
7849654 - 财政年份:2007
- 资助金额:
$ 36.12万 - 项目类别:
Engineering AAV Vectors to Evade Antibody Neutralization
设计 AAV 载体以逃避抗体中和
- 批准号:
7208807 - 财政年份:2007
- 资助金额:
$ 36.12万 - 项目类别:
Engineering AAV Vectors to Evade Antibody Neutralization
设计 AAV 载体以逃避抗体中和
- 批准号:
7626787 - 财政年份:2007
- 资助金额:
$ 36.12万 - 项目类别:
Engineering AAV Vectors to Evade Antibody Neutralization
设计 AAV 载体以逃避抗体中和
- 批准号:
7851669 - 财政年份:2007
- 资助金额:
$ 36.12万 - 项目类别:
Engineering Novel AAV Vectors for Retinal Gene Therapy
用于视网膜基因治疗的新型 AAV 载体工程
- 批准号:
7268010 - 财政年份:2006
- 资助金额:
$ 36.12万 - 项目类别:
Engineering Novel AAV Vectors for Retinal Gene Therapy
用于视网膜基因治疗的新型 AAV 载体工程
- 批准号:
7149417 - 财政年份:2006
- 资助金额:
$ 36.12万 - 项目类别:
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 36.12万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 36.12万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 36.12万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 36.12万 - 项目类别:
Discovery Early Career Researcher Award
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 36.12万 - 项目类别:
Continuing Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 36.12万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 36.12万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Analysis of thermoregulatory mechanisms by the CNS using model animals of female-dominant infectious hypothermia
使用雌性传染性低体温模型动物分析中枢神经系统的体温调节机制
- 批准号:
23KK0126 - 财政年份:2023
- 资助金额:
$ 36.12万 - 项目类别:
Fund for the Promotion of Joint International Research (International Collaborative Research)
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 36.12万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 36.12万 - 项目类别:
Training Grant